Search

Your search keyword '"Desselle, Ariane"' showing total 8 results
Start Over Author "Desselle, Ariane" Search Limiters Full Text
8 results on '"Desselle, Ariane"'

2. CLEC-1 is a death sensor that limits antigen cross-presentation by dendritic cells and represents a target for cancer immunotherapy

Author

Drouin, Marion, primary, Saenz, Javier, additional, Gauttier, Vanessa, additional, Evrard, Berangere, additional, Teppaz, Geraldine, additional, Pengam, Sabrina, additional, Mary, Caroline, additional, Desselle, Ariane, additional, Thepenier, Virginie, additional, Wilhelm, Emmanuelle, additional, Merieau, Emmanuel, additional, Ligeron, Camille, additional, Girault, Isabelle, additional, Lopez, Maria-Dolores, additional, Fourgeux, Cynthia, additional, Sinha, Debajyoti, additional, Baccelli, Irene, additional, Moreau, Aurelie, additional, Louvet, Cedric, additional, Josien, Regis, additional, Poschmann, Jeremie, additional, Poirier, Nicolas, additional, and Chiffoleau, Elise, additional

Published
2022
Full Text
View/download PDF

3. 230 Preclinical efficacy of CLEC-1 antagonist as novel myeloid immune checkpoint therapy for oncology

Author

Gauttier, Vanessa, primary, Drouin, Marion, additional, Pengam, Sabrina, additional, Saenz, Javier, additional, Evrard, Bérangère, additional, Neyton, Stéphanie, additional, Mary, caroline, additional, Teppaz, Géraldine, additional, Desselle, Ariane, additional, Thépénier, Virginie, additional, Wilhelm, Emmanuelle, additional, Poirier, Nicolas, additional, and Chiffoleau, Elise, additional

Published
2021
Full Text
View/download PDF

4. 212 CLEC-1 is a novel myeloid immune checkpoint for cancer immunotherapy limiting tumor cells phagocytosis and synergizing with tumor-targeted antibodies

Author

Gauttier, Vanessa, primary, Drouin, Marion, additional, Pengam, Sabrina, additional, Saenz, Javier, additional, Evrard, Bérangère, additional, Mary, Caroline, additional, Teppaz, Géraldine, additional, Desselle, Ariane, additional, Thépénier, Virginie, additional, Wilhelm, Emmanuelle, additional, Chiffoleau, Elise, additional, and Poirier, Nicolas, additional

Published
2020
Full Text
View/download PDF

5. Nanofitin as a New Molecular-Imaging Agent for the Diagnosis of Epidermal Growth Factor Receptor Over-Expressing Tumors

Author

Goux, Marine, Doumont, Gilles, Plenevaux, Alain, Cinier, Mathieu, Luxen, André, Becker, Guillaume, Gorré, Harmony, Dammicco, Sylvestre, Desselle, Ariane, Egrise, Dominique, Leroi, Natacha, Lallemand, Françoise, Bahri, Mohamed Ali, Goux, Marine, Doumont, Gilles, Plenevaux, Alain, Cinier, Mathieu, Luxen, André, Becker, Guillaume, Gorré, Harmony, Dammicco, Sylvestre, Desselle, Ariane, Egrise, Dominique, Leroi, Natacha, Lallemand, Françoise, and Bahri, Mohamed Ali

Abstract

Epidermal growth-factor receptor (EGFR) is involved in cell growth and proliferation and is over-expressed in malignant tissues. Although anti-EGFR-based immunotherapy became a standard of care for patients with EGFR-positive tumors, this strategy of addressing cancer tumors by targeting EGFR with monoclonal antibodies is less-developed for patient diagnostic and monitoring. Indeed, antibodies exhibit a slow blood clearance, which is detrimental for positron emission tomography (PET) imaging. New molecular probes are proposed to overcome such limitations for patient monitoring, making use of low-molecular-weight protein scaffolds as alternatives to antibodies, such as Nanofitins with better pharmacokinetic profiles. Anti-EGFR Nanofitin B10 was reformatted by genetic engineering to exhibit a unique cysteine moiety at its C-terminus, which allows the development of a fast and site-specific radiolabeling procedure with 18F-4-fluorobenzamido-N-ethylamino-maleimide (18F-FBEM). The in vivo tumor targeting and imaging profile of the anti-EGFR Cys-B10 Nanofitin was investigated in a double-tumor xenograft model by static small-animal PET at 2 h after tail-vein injection of the radiolabeled Nanofitin 18F-FBEM-Cys-B10. The image showed that the EGFR-positive tumor (A431) is clearly delineated in comparison to the EGFR-negative tumor (H520) with a significant tumor-to-background contrast. 18F-FBEM-Cys-B10 demonstrated a significantly higher retention in A431 tumors than in H520 tumors at 2.5 h post-injection with a A431-to-H520 uptake ratio of 2.53 ± 0.18 and a tumor-to-blood ratio of 4.55 ± 0.63. This study provides the first report of Nanofitin scaffold used as a targeted PET radiotracer for in vivo imaging of EGFR-positive tumor, with the anti-EGFR B10 Nanofitin used as proof-of-concept. The fast generation of specific Nanofitins via a fully in vitro selection process, together with the excellent imaging features of the Nanofitin scaffold, could facilitate the development o, SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2017

8. A Monoclonal Antibody to O-Acetyl-GD2 Ganglioside and Not to GD2 Shows Potent Anti-Tumor Activity without Peripheral Nervous System Cross-Reactivity

Author

Alvarez-Rueda, Nidia, primary, Desselle, Ariane, additional, Cochonneau, Denis, additional, Chaumette, Tanguy, additional, Clemenceau, Béatrice, additional, Leprieur, Stéphanie, additional, Bougras, Gwenola, additional, Supiot, Stéphane, additional, Mussini, Jean-Marie, additional, Barbet, Jacques, additional, Saba, Julie, additional, Paris, François, additional, Aubry, Jacques, additional, and Birklé, Stéphane, additional

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results